Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Lucintel | PRODUCT CODE: 1386082

Cover Image

PUBLISHER: Lucintel | PRODUCT CODE: 1386082

Cancer Biomarkers Market Report: Trends, Forecast and Competitive Analysis to 2030

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4850
PDF (2 Users License)
USD 5800
PDF (5 Users License)
USD 6700
PDF (Corporate License)
USD 8850

Add to Cart

Cancer Biomarkers Trends and Forecast

The future of the global cancer biomarkers market looks promising with opportunities in the diagnostics, R&D, prognostics, and risk management markets. The global cancer biomarkers market is expected to reach an estimated $37.7 billion by 2030 with a CAGR of 14.5% from 2024 to 2030. The major drivers for this market are increasing inclination towards personalized medicine for cancer treatment, growing awareness towards importance of early detection of cancer, and rising government support for cancer research.

A more than 150-page report is developed to help in your business decisions.

Cancer Biomarkers by Segment

The study includes a forecast for the global cancer biomarkers by type, cancer, profiling technology, application, and region.

Cancer Biomarkers Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Protein
  • Genetic
  • Others

Cancer Biomarkers Market by Cancer [Shipment Analysis by Value from 2018 to 2030]:

  • Lung
  • Breast
  • Leukemia
  • Melanoma
  • Colorectal
  • Prostate
  • Thyroid
  • Kidney
  • Others

Cancer Biomarkers Market by Profiling Technology [Shipment Analysis by Value from 2018 to 2030]:

  • Omics
  • Imaging
  • Immunoassay
  • Bioinformatics
  • Others

Cancer Biomarkers Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Diagnostics
  • R&D
  • Prognostics
  • Risk Management
  • Others

Cancer Biomarkers Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Cancer Biomarkers Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cancer biomarkers companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer biomarkers companies profiled in this report include-

  • F. Hoffmann-La Roche
  • Thermo Fisher Scientific
  • Illumina
  • Qiagen N.V.
  • Bio-Rad Laboratories

Cancer Biomarkers Market Insights

Lucintel forecasts that breast cancer will remain the largest segment over the forecast period due to increasing incidence of breast cancer and rising awareness of the diagnosis of this disease.

Within this market, diagnostic will remain the largest segment due to increasing prevalence of cancer and growing availability of cancer screening programs.

North America will remain the largest region during the forecast period due to presence of well-established healthcare systems, rising incidence of cancer, and easy accessibility to advanced healthcare technologies in the region.

Features of the Global Cancer Biomarkers Market

Market Size Estimates: Cancer biomarkers market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cancer biomarkers market size by various segments, such as by type, cancer type, profiling technology, application, and region in terms of ($B).

Regional Analysis: Cancer biomarkers market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, cancer types, profiling technologies, applications, and regions for the cancer biomarkers market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer biomarkers market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the cancer biomarkers market size?

Answer: The global cancer biomarkers market is expected to reach an estimated $37.7 billion by 2030.

Q.2 What is the growth forecast for cancer biomarkers market?

Answer: The global cancer biomarkers market is expected to grow with a CAGR of 14.5% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the cancer biomarkers market?

Answer: The major drivers for this market are increasing inclination towards personalized medicine for cancer treatment, growing awareness towards importance of early detection of cancer, and rising government support for cancer research.

Q4. What are the major segments for cancer biomarkers market?

Answer: The future of the cancer biomarkers market looks promising with opportunities in the diagnostics, R&D, prognostics, and risk management markets.

Q5. Who are the key cancer biomarkers market companies?

Answer: Some of the key cancer biomarkers companies are as follows:

  • F. Hoffmann-La Roche
  • Thermo Fisher Scientific
  • Illumina
  • Qiagen N.V.
  • Bio-Rad Laboratories

Q6. Which cancer biomarkers market segment will be the largest in future?

Answer: Lucintel forecasts that breast cancer will remain the largest segment over the forecast period due to increasing incidence of breast cancer and rising awareness of the diagnosis of this disease.

Q7. In cancer biomarkers market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region during the forecast period due to presence of well-established healthcare systems, rising incidence of cancer, and easy accessibility to advanced healthcare technologies in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the cancer biomarkers market by type (protein, genetic, and others), cancer type (lung, breast, leukemia, melanoma, colorectal, prostate, thyroid, kidney, and others), profiling technology (omics, imaging, immunoassay, bioinformatics, and others), application (diagnostics, R&D, prognostics, risk management, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cancer Biomarkers Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Cancer Biomarkers Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Cancer Biomarkers Market by Type
    • 3.3.1: Protein
    • 3.3.2: Genetic
    • 3.3.3: Others
  • 3.4: Global Cancer Biomarkers Market by Cancer Type
    • 3.4.1: Lung
    • 3.4.2: Breast
    • 3.4.3: Leukemia
    • 3.4.4: Melanoma
    • 3.4.5: Colorectal
    • 3.4.6: Prostate
    • 3.4.7: Thyroid
    • 3.4.8: Kidney
    • 3.4.9: Others
  • 3.5: Global Cancer Biomarkers Market by Profiling Technology
    • 3.5.1: Omics
    • 3.5.2: Imaging
    • 3.5.3: Immunoassay
    • 3.5.4: Bioinformatics
    • 3.5.5: Others
  • 3.6: Global Cancer Biomarkers Market by Application
    • 3.6.1: Diagnostics
    • 3.6.2: R&D
    • 3.6.3: Prognostics
    • 3.6.4: Risk Management
    • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Cancer Biomarkers Market by Region
  • 4.2: North American Cancer Biomarkers Market
    • 4.2.2: North American Cancer Biomarkers Market by Application: Diagnostics, R&D, Prognostics, Risk Management, and Others
  • 4.3: European Cancer Biomarkers Market
    • 4.3.1: European Cancer Biomarkers Market by Cancer Type: Lung, Breast, Leukemia, Melanoma, Colorectal, Prostate, Thyroid, Kidney, and Others
    • 4.3.2: European Cancer Biomarkers Market by Application: Diagnostics, R&D, Prognostics, Risk Management, and Others
  • 4.4: APAC Cancer Biomarkers Market
    • 4.4.1: APAC Cancer Biomarkers Market by Cancer Type: Lung, Breast, Leukemia, Melanoma, Colorectal, Prostate, Thyroid, Kidney, and Others
    • 4.4.2: APAC Cancer Biomarkers Market by Application: Diagnostics, R&D, Prognostics, Risk Management, and Others
  • 4.5: ROW Cancer Biomarkers Market
    • 4.5.1: ROW Cancer Biomarkers Market by Cancer Type: Lung, Breast, Leukemia, Melanoma, Colorectal, Prostate, Thyroid, Kidney, and Others
    • 4.5.2: ROW Cancer Biomarkers Market by Application: Diagnostics, R&D, Prognostics, Risk Management, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Cancer Biomarkers Market by Type
    • 6.1.2: Growth Opportunities for the Global Cancer Biomarkers Market by Cancer Type
    • 6.1.3: Growth Opportunities for the Global Cancer Biomarkers Market by Profiling Technology
    • 6.1.4: Growth Opportunities for the Global Cancer Biomarkers Market by Application
    • 6.1.5: Growth Opportunities for the Global Cancer Biomarkers Market by Region
  • 6.2: Emerging Trends in the Global Cancer Biomarkers Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Cancer Biomarkers Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cancer Biomarkers Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: F. Hoffmann-La Roche
  • 7.2: Thermo Fisher Scientific
  • 7.3: Illumina
  • 7.4: QIAGEN N.V.
  • 7.5: Bio-Rad Laboratories
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!